lncRNAs MYOSLID 和 SFTA1P 在结直肠癌患者中的失调及其临床相关性。

The dysregulation and clinical relevance of lncRNAs MYOSLID and SFTA1P in colorectal cancer patients.

机构信息

Department of Genetic, Faculty of Sciences, Islamic Azad University of Qom, Qom, Iran.

Department of Biology, Faculty of Basic Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran.

出版信息

Mol Biol Rep. 2024 Oct 30;51(1):1109. doi: 10.1007/s11033-024-10020-x.

DOI:10.1007/s11033-024-10020-x

PMID:39476151

Abstract

BACKGROUND

Colorectal cancer (CRC) is a very common cancer worldwide. CRC is characterized by some changes in the expression of oncogenic and tumor suppressor genes. These changes are associated with dysregulation of non-coding RNAs, including long non-coding RNAs (lncRNAs). LncRNAs are heterogeneous non-coding molecules without open reading frames. LncRNAs have been established as regulators in the development of CRC and clinical biomarkers for the CRC detection. In this project, we investigated the expression changes of two new lncRNAs named SFTA1P and MYOSLID in CRC patients.

MATERIALS AND METHODS

30 samples of CRC tissue and 30 samples of normal tissue adjacent to the cancer tissue were obtained from patients. RNA extraction from tissue samples was performed using RNAX plus. ExcelRT™ Reverse Transcription Kit (SymBio, Korea) was used for cDNA synthesis. RealQ Plus 2x Master Mix Green Without ROX™ was used to perform a quantitative PCR (qPCR). REST, and SPSS software were used for statistical analysis.

RESULT

Our result demonstrated that lncRNAs MYOSLID and SFTA1P were significantly up-regulated in tumor tissues compared to healthy tissues with a fold change of 13.43 and 5.33 (P < 0.05) respectively. Based on the analysis of ROC curve, MYOSLID (AUC = 0.946, P < 0.0001, SE =0.0035) and SFTA1P (AUC = 0.800, P < 0.0001, SE = 0.059) were indicated as potential clinical hallmarks for CRC patients.

CONCLUSION

According to the results obtained from this research, lncRNAs SFTA1P and MYOSLID can be suggested as molecular biomarkers for the CRC diagnosis.

摘要

背景

结直肠癌（CRC）是一种在全球范围内非常常见的癌症。CRC 的特征是一些致癌基因和肿瘤抑制基因的表达发生变化。这些变化与非编码 RNA（包括长非编码 RNA（lncRNA））的失调有关。lncRNA 是没有开放阅读框的异质非编码分子。lncRNA 已被确定为 CRC 发展的调节剂和 CRC 检测的临床生物标志物。在本项目中，我们研究了两种新的 lncRNA，即 SFTA1P 和 MYOSLID，在 CRC 患者中的表达变化。

材料和方法

从患者中获得了 30 个 CRC 组织样本和 30 个与癌症组织相邻的正常组织样本。使用 RNAX plus 从组织样本中提取 RNA。使用 ExcelRT™ Reverse Transcription Kit（SymBio，韩国）合成 cDNA。使用 RealQ Plus 2x Master Mix Green Without ROX™ 进行实时定量 PCR（qPCR）。使用 REST 和 SPSS 软件进行统计分析。

结果

我们的结果表明，与健康组织相比，lncRNA MYOSLID 和 SFTA1P 在肿瘤组织中显著上调，倍数变化分别为 13.43 和 5.33（P < 0.05）。基于 ROC 曲线分析，MYOSLID（AUC = 0.946，P < 0.0001，SE = 0.0035）和 SFTA1P（AUC = 0.800，P < 0.0001，SE = 0.059）被认为是 CRC 患者的潜在临床标志物。